303 related articles for article (PubMed ID: 37365276)
1. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines.
Han X; Alameh MG; Butowska K; Knox JJ; Lundgreen K; Ghattas M; Gong N; Xue L; Xu Y; Lavertu M; Bates P; Xu J; Nie G; Zhong Y; Weissman D; Mitchell MJ
Nat Nanotechnol; 2023 Sep; 18(9):1105-1114. PubMed ID: 37365276
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses.
Alameh MG; Tombácz I; Bettini E; Lederer K; Sittplangkoon C; Wilmore JR; Gaudette BT; Soliman OY; Pine M; Hicks P; Manzoni TB; Knox JJ; Johnson JL; Laczkó D; Muramatsu H; Davis B; Meng W; Rosenfeld AM; Strohmeier S; Lin PJC; Mui BL; Tam YK; Karikó K; Jacquet A; Krammer F; Bates P; Cancro MP; Weissman D; Luning Prak ET; Allman D; Locci M; Pardi N
Immunity; 2021 Dec; 54(12):2877-2892.e7. PubMed ID: 34852217
[TBL] [Abstract][Full Text] [Related]
3. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
Takanashi A; Pouton CW; Al-Wassiti H
Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
[TBL] [Abstract][Full Text] [Related]
4. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
[TBL] [Abstract][Full Text] [Related]
5. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.
Vadovics M; Muramatsu H; Sárközy A; Pardi N
Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394
[TBL] [Abstract][Full Text] [Related]
6. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
[TBL] [Abstract][Full Text] [Related]
7. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion.
Qin Z; Bouteau A; Herbst C; Igyártó BZ
PLoS Pathog; 2022 Sep; 18(9):e1010830. PubMed ID: 36054264
[TBL] [Abstract][Full Text] [Related]
8. Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria.
Meulewaeter S; Aernout I; Deprez J; Engelen Y; De Velder M; Franceschini L; Breckpot K; Van Calenbergh S; Asselman C; Boucher K; Impens F; De Smedt SC; Verbeke R; Lentacker I
J Control Release; 2024 Jun; 370():379-391. PubMed ID: 38697317
[TBL] [Abstract][Full Text] [Related]
9. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab.
Jarzebska NT; Frei J; Mellett M; Kündig TM; Pascolo S; Reichmuth AM
Methods Mol Biol; 2024; 2786():237-254. PubMed ID: 38814398
[TBL] [Abstract][Full Text] [Related]
10. STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2.
Zhang Y; Yan J; Hou X; Wang C; Kang DD; Xue Y; Du S; Deng B; McComb DW; Liu SL; Zhong Y; Dong Y
Nano Lett; 2023 Apr; 23(7):2593-2600. PubMed ID: 36942873
[TBL] [Abstract][Full Text] [Related]
11. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
Ye Z; Bonam SR; McKay LGA; Plante JA; Walker J; Zhao Y; Huang C; Chen J; Xu C; Li Y; Liu L; Harmon J; Gao S; Song D; Zhang Z; Plante KS; Griffiths A; Chen J; Hu H; Xu Q
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2311752120. PubMed ID: 38134199
[TBL] [Abstract][Full Text] [Related]
12. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
13. Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery.
van Rijn CJM; Vlaming KE; Bem RA; Dekker RJ; Poortinga A; Breit T; van Leeuwen S; Ensink WA; van Wijnbergen K; van Hamme JL; Bonn D; Geijtenbeek TBH
Sci Rep; 2023 May; 13(1):8851. PubMed ID: 37258559
[TBL] [Abstract][Full Text] [Related]
14. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D
Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810
[TBL] [Abstract][Full Text] [Related]
15. Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.
Zamani P; Mashreghi M; Rezazade Bazaz M; Zargari S; Alizadeh F; Dorrigiv M; Abdoli A; Aminianfar H; Hatamipour M; Zarqi J; Behboodifar S; Samsami Y; Khorshid Sokhangouy S; Sefidbakht Y; Uskoković V; Rezayat SM; Jaafari MR; Mozaffari-Jovin S
J Control Release; 2023 Aug; 360():316-334. PubMed ID: 37355212
[TBL] [Abstract][Full Text] [Related]
16. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
[TBL] [Abstract][Full Text] [Related]
17. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles.
Wang J; Zhang Y; Dong S; Zha W; Liu C; Wang Y; Jiang Y; Xing H; Li X
Int J Pharm; 2023 Jul; 642():123155. PubMed ID: 37402442
[TBL] [Abstract][Full Text] [Related]
18. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
[TBL] [Abstract][Full Text] [Related]
19. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines.
Li Z; Zhang XQ; Ho W; Li F; Gao M; Bai X; Xu X
ACS Nano; 2022 Nov; 16(11):18936-18950. PubMed ID: 36269150
[TBL] [Abstract][Full Text] [Related]
20. Innate immune mechanisms of mRNA vaccines.
Verbeke R; Hogan MJ; Loré K; Pardi N
Immunity; 2022 Nov; 55(11):1993-2005. PubMed ID: 36351374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
